TEVA, US8816242098

TEVA stock gets new ecopipam data before Q3 results

Published on 10/07/2026 at 09:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TEVA stock was last at USD 39.13 on October 6, 2026, after new ecopipam data. TD Cowen set a USD 55 target before Teva reports on November 3.

TEVA, US8816242098, Illustration mit AI erstellt.

TEVA stock was last at USD 39.13 on the NYSE on October 6, 2026, down 1.34 percent from the prior session. The latest company catalyst is ecopipam, where data presented on October 2 showed a clinically meaningful reduction in tic severity for 69.8 percent of 292 pediatric patients within eight weeks.

Ecopipam adds pipeline evidence

According to finanzen.ch on October 2, 2026, an interim open-label extension analysis found a 45.6 percent mean reduction in tic severity through 18 months among 118 participants. The analysis reported a median treatment exposure of 14.9 months and no new safety signals.

The data remain clinical-stage evidence rather than product revenue. Teva's program includes Phase 2b and Phase 3 studies, so the commercial value depends on later trial results and regulatory decisions.

Analysts see further upside

According to MarketBeat on October 1, 2026, TD Cowen initiated coverage with a Buy rating and a USD 55 price target. That target stands 40.5 percent above the USD 39.13 last price.

The same MarketBeat report described a Moderate Buy consensus from 13 analysts, with 12 Buy ratings and one Hold rating. The average target was USD 44.67, which is 14.2 percent above the October 6 price.

Q3 results set the next test

Teva reported USD 4.14 billion in Q2 2026 revenue and adjusted EPS of USD 0.63, according to Investing.com. The company also reported GAAP EPS of USD 0.02 for the quarter, making the distinction between adjusted performance and reported earnings material for the next update.

Teva said its Q3 2026 results are scheduled for November 3, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET. That release will test whether pipeline expectations are being matched by operating performance.

TEVA stock remains near its yearly high

TEVA was last at USD 39.13 on the NYSE on October 6, 2026, against a 52-week range of USD 18.83 to USD 40.79. The market capitalization was USD 45.6 billion and volume was 5,716,393 shares on that date.